Stock Splits
By The Online Investor Staff, updated Mon., Nov. 11, 10:04 PM
| This Slide: #3 of 25 |
Slide #3. Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) — 1 for 10 Reverse Split
Announced:
10/31/2019
Stock Split:
1 for 10
Record Date:
10/31/2019
Pay Date:
11/1/2019
TNXP Optionable?:
No
Tonix Pharmaceuticals Holding is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Co.'s main drug development program is focused on delivering a long-term treatment for posttraumatic stress disorder. Co.'s primary product candidate, Tonmya, or TNX-102 SL, is a proprietary low-dose cyclobenzaprine sublingual tablet, designed for bedtime administration. TNX-102 SL is also being developed as a bedtime treatment for Fibromyalgia, and agitation in Alzheimer's disease. 
TNXP Detailed Information Page & Split History »
|
||||||||||||||||||||||||
Open the TNXP Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 80th percentile
(ranked higher than approx. 80% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
